Acceleron  

Publications

  • Publication
    Luspatercept
    Dec 5, 2016
    Luspatercept Increases Hemoglobin, Decreases Transfusion Burden, and Improves Patient-Reported Outcomes in Adults with Beta-Thalassemia
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 4, 2016
    Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study. ASH 2016; December 6th, 2017.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 4, 2016
    Pharmacokinetics and Exposure–Response of Luspatercept in Patients With Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results From Phase 2 Studies
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 4, 2016
    Pharmacokinetics and Exposure–Response of Luspatercept in Patients With Beta-Thalassemia: Preliminary Results From Phase 2 Studies
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Dec 1, 2016
    A Phase 2 Study of Dalantercept, an Activin Receptor-Like Kinase-1 Ligand Trap, in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancer. December 1, 2016; 122(23):3641-3649
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Nov 11, 2016
    Luspatercept Posters at the 2016 TIF 2nd MEGMA Conference on Thalassaemia and Other Haemoglobinopathies; November 11-12, 2016
    + VIEW FULL Publication
  • Publication
    ACE-083
    Nov 10, 2016
    A Phase 2 study to evaluate ACE-083, a local muscle therapeutic, in patients with FSHD. FSH Society 2016 Research Connect Conference; November 10, 2016.
    + VIEW FULL Publication
  • Publication
    ACE-083
    Oct 6, 2016
    A Phase 1 Healthy Volunteer Study of ACE-083, a Novel, Locally-Acting Muscle Agent. Patient-Centered Charcot-Marie-Tooth Summit; October 6, 2016.
    + VIEW FULL Publication
  • Publication
    ACE-083
    Sep 9, 2016
    A Phase 1 Healthy Volunteer Study of ACE-083, a Novel, Locally-Acting Muscle Agent. 6th International CMTR Consortium Meeting; September 9, 2016.
    + VIEW FULL Publication
  • Publication
    ACE-083
    Jul 8, 2016
    ACE-083, A Locally-Acting Muscle Agent, Increases Muscle Volume In Healthy Volunteers. 14th International Congress on Neuromuscular Diseases; July 8, 2016.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 12, 2016
    Luspatercept Decreases Transfusion Burden and Liver Iron Concentration in Regularly Transfused Adults with Beta-Thalassemia. 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 11, 2016
    Luspatercept Increases Hemoglobin, Reduces Liver Iron Concentration and Improves Quality of Life in Non-Transfusion Dependent Adults with Beta-Thalassemia. 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    Jun 10, 2016
    ACE-1332 Inhibits Elevated TGFβ1 Signaling and Reduces Fibrosis in a Murine Model of Myelofibrosis. 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 10, 2016
    RAP-536 (Murine Analog of ACE-536/Luspatercept) Inhibits SMAD2/3 Signaling and Promotes Erythroid Differentiation by Restoring GATA-1 Function in a Murine Model of Beta-Thalassemia; 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 10, 2016
    Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low- Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE‐MDS Study; 21st Congress of the European Hematology Association; June 9-12, 2016
    + VIEW FULL Publication
  • Publication
    ACE-083
    Apr 2, 2016
    ACE-083, a Locally-Acting TGF-Beta Superfamily Ligand Trap, Increases Muscle Volume of Targeted Muscle: Preliminary Results from a Phase 1 Dose Escalation Study in Healthy Volunteers. ENDO 2016; April 1-4, 2016.
    + VIEW FULL Publication
  • Publication
    ACE-083
    Mar 21, 2016
    ACE-083, a locally-acting TGF-beta superfamily ligand trap, increases muscle volume of targeted muscle: Preliminary results from a Phase 1 dose escalation study in healthy volunteers. 2016 MDA Clinical Conference; March 20-23, 2016.
    + VIEW FULL Publication
  • Publication
    ACE-083
    Mar 21, 2016
    ACE-083, a Locally-Acting TGF-β Superfamily Ligand Trap, Increases Muscle Mass and Strength in a Mouse Model of ALS. 2016 MDA Clinical Conference; March 20-23, 2016.
    + VIEW FULL Publication